CureVac and GlaxoSmithKline's first attempt ... with more coming down the pipeline – including GSK and Sanofi's recombinant protein candidate – and prospects looking slim in an increasingly ...

Emerging tools enable more accurate antigen production and presentation using mRNA instead of protein. In recent years, mRNA technology has come into its own, most prominently in the field of vaccine ...

In the case of GSK’s recombinant ... protein-based candidate vaccines with Sanofi and SK bioscience, the adjuvanted plant-based vaccine with Medicago, and next-generation mRNA vaccines with CureVac.

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market capitalization of $818.75 million, stands at a critical juncture in its ...

Tesla Inc is building mobile molecule printers to help make the potential Covid-19 vaccine being developed by CureVac in Germany, the electric-car maker's CEO Elon Musk tweeted on July 1.